Sélection · Santé

Biotech

Par InspectStocksPublished 14 oct. 202619 companies0 follower

Drug developers with approved medicines, built mainly on biologic and genetic science.

Regroupées avec l’aide d’un modèle d’IA et relues par notre rédaction. La ligne sous chaque entreprise indique pourquoi elle figure ici.

Download image

Cartes Niveaux

Les cours sont ceux de la clôture du 11 nov. 2026, issus du flux de la bourse IEX.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29,0 %

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap 138,7B $USP/E 35,22
547,02 $US+26,0 %1Y
Since added +12,7 %
B+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
13B $US+10,5 %
Profit
4B $US+8,2 %
Free cash flow
3,2B $US-4,0 %
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap 101,3B $USP/E 21,18
959,45 $US+41,5 %1Y
Since added +27,4 %
C+
Croissance et trésorerie
En croissance
Business trend
En accélération
Business quality
Forte
Getting better
En amélioration
Revenue
16,9B $US+18,6 %
Profit
4,8B $US+5,2 %
Free cash flow
3,8B $US-9,4 %
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap 210,5B $USPas de PER (perte d’exploitation)
169,73 $US+40,9 %1Y
Since added +14,8 %
A
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Contrastée
Getting better
En amélioration
Revenue
31B $US+6,5 %
Profit
-3,9B $US-147,6 %
Free cash flow
13,8B $US+50,4 %
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap 21,4B $USP/E 68,58
159,80 $US-64,7 %1Y
Since added -28,6 %
B+
Croissance et trésorerie
Croissance forte
Business trend
En ralentissement
Business quality
Forte
Getting better
En amélioration
Revenue
3,7B $US+65,2 %
Profit
2,6B $US+2 136,9 %
Free cash flow
465,4M $US+1 192,7 %
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap 37,5B $USP/E 109,22
253,39 $US+56,9 %1Y
Since added +10,7 %
A
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Solide
Getting better
Contrasté
Revenue
10,3B $US+2,3 %
Profit
347,5M $US-78,4 %
Free cash flow
2,1B $US-10,1 %
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap 26,5B $USPas de PER (perte d’exploitation)
120,64 $US-37,9 %1Y
Since added +24,7 %
C-
Croissance et trésorerie
En croissance
Business trend
Stable
Business quality
Faible
Getting better
Contrasté
Revenue
1,5B $US+240,0 %
Profit
-605,6M $US+48,8 %
Free cash flow
-627,6M $US+30,7 %
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap 25,4B $USP/E 22,48
595,58 $US+29,0 %1Y
Since added +9,6 %
C+
Croissance et trésorerie
Croissance forte
Business trend
En ralentissement
Business quality
Forte
Getting better
En nette amélioration
Revenue
3,2B $US+1,9 %
Profit
1,2B $US-3,2 %
Free cash flow
867,2M $US-22,7 %
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap 17,6B $USP/E 25,87
174,35 $US+18,7 %1Y
Since added +29,0 %
A+
Croissance et trésorerie
Croissance forte
Business trend
En accélération
Business quality
Forte
Getting better
En amélioration
Revenue
3,7B $US+38,0 %
Profit
702,5M $US+64,1 %
Free cash flow
1B $US+75,3 %
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap 100,6B $USPas de PER (perte d’exploitation)
248,70 $US+831,1 %1Y
Since added +15,0 %
C-
Croissance et trésorerie
En croissance
Business trend
En accélération
Business quality
Faible
Getting better
En dégradation
Revenue
2,5B $US+13,1 %
Profit
-2,8B $US+10,5 %
Free cash flow
-2B $US+25,7 %
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap 11,3B $USNo P/E
58,32 $US+5,4 %1Y
Since added +7,3 %
B
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Contrastée
Getting better
En amélioration
Revenue
3,7B $US+18,1 %
Profit
-19,1M $US-103,7 %
Free cash flow
557,9M $US-33,0 %
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap 24,9B $USP/E 65,01
122,23 $US+12,9 %1Y
Since added +12,6 %
C
Résultat et actif net
En croissance
Business quality
Contrastée
Getting better
En nette amélioration
Revenue
6B $US+24,9 %
Profit
403,4M $US-66,1 %
Free cash flow
892,1M $USNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap 17,3B $USP/E 21,17
70,71 $US+62,2 %1Y
Since added +18,8 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
2,5B $US+9,1 %
Profit
885,1M $US+30,6 %
Free cash flow
1,2B $US+48,9 %
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap 22B $USPas de PER (perte d’exploitation)
87,64 $US-21,5 %1Y
Since added -1,5 %
F
Croissance et trésorerie
Contrasté
Business trend
En contraction
Business quality
Contrastée
Getting better
En amélioration
Revenue
2,7B $US-23,2 %
Profit
-1,6B $US-157,7 %
Free cash flow
314M $US+456,5 %
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap 15,9B $USP/E 80,84
248,18 $US+81,5 %1Y
Since added +18,0 %
A
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Contrastée
Getting better
En amélioration
Revenue
4,7B $US+13,5 %
Profit
206M $US+155,9 %
Free cash flow
1,6B $US+21,3 %
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap 11,6B $USP/E 25,36
101,69 $US+44,0 %1Y
Since added -7,2 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
1,8B $US+45,0 %
Profit
485,4M $US-18,5 %
Free cash flow
885,9M $US+47,1 %
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap 16,1B $USPas de PER (perte d’exploitation)
259,10 $US+30,1 %1Y
Since added +16,0 %
D
Résultat et actif net
Contrasté
Business quality
Contrastée
Getting better
En amélioration
Revenue
1,2B $US+113,4 %
Profit
-254,8M $US+39,7 %
Free cash flow
-293,2M $US+54,2 %
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap 15,5B $USPas de PER (perte d’exploitation)
79,53 $US+20,1 %1Y
Since added +25,6 %
B
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Contrastée
Getting better
En dégradation
Revenue
945,5M $US+167,3 %
Profit
-573,8M $US+28,6 %
Free cash flow
-369,8M $US+36,9 %
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap 8,2B $USP/E 58,68
74,52 $US-4,9 %1Y
Since added -36,7 %
A+
Croissance et trésorerie
Croissance forte
Business trend
En accélération
Business quality
Forte
Getting better
Contrasté
Revenue
963,6M $US+30,0 %
Profit
162,3M $US+52,9 %
Free cash flow
194,6M $US+19,2 %
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap 9,2B $USP/E 41,90
308,82 $US+52,1 %1Y
Since added -3,9 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
470M $US+26,0 %
Profit
225,2M $US+13,2 %
Free cash flow
310,1M $US+87,3 %
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.